Surgery – Respiratory method or device – Ozone or ion generation
Patent
1979-02-09
1980-08-12
Kamm, William E.
Surgery
Respiratory method or device
Ozone or ion generation
233 1R, 210DIG23, A61M 500, B01D 2126
Patent
active
042167701
ABSTRACT:
A sickle cell therapeutic treatment is provided by means of continuous flow red blood cell carbamylation. In a substantially continuous process, whole blood is removed from a patient and is directed to a red cell separator chamber of a seal-less type centrifuge. The whole blood is centrifuged and the red blood cells to be treated are removed from the red cell separation chamber and are directed to a reaction chamber. An anti-sickle agent, such as cyanate solution, is introduced into the reaction chamber and is mixed with the red blood cells to be treated. The mixed anti-sickle agent and red blood cells are transferred to a wash chamber in the centrifuge where they are washed, by centrifugation, and the washed, treated red blood cells are combined with the plasma that was separated in the red cell separation chamber and the combination is returned to the patient.
REFERENCES:
patent: 2876769 (1959-03-01), Cordova
patent: 3462361 (1969-08-01), Greenwalt et al.
patent: 3489145 (1970-01-01), Judson et al.
patent: 3833724 (1974-09-01), Cerami et al.
patent: 3856624 (1974-12-01), Kraus et al.
patent: 4048325 (1977-09-01), Packer et al.
patent: 4151844 (1979-04-01), Cullis et al.
Carbamyl Phosphate Mediated Inhibition of the Sickling of Erythrocytes in Vivo, Kraus et al., Biochemical and Biophysical Research Communications, vol. 44, No. 6, 1971, pp. 1381-1387.
Cullis Herbert M.
Dorsey Evelyn E.
Baxter Travenol Laboratories Inc.
Collins H. W.
Flattery Paul C.
Gerstman George H.
Kamm William E.
LandOfFree
Sickle cell therapeutic treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sickle cell therapeutic treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sickle cell therapeutic treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2178747